Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03294694 |
|
Recruitment Status :
Terminated
(Safety Implications)
First Posted : September 27, 2017
Last Update Posted : March 31, 2022
|
Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Novartis
Information provided by (Responsible Party):
Sara Tolaney, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | October 14, 2020 |
| Actual Study Completion Date : | October 14, 2020 |